Skip Navigation
Search Menu

Print This Page
Share this page: More

Search Results

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors.
Protocol Number:
Phase I
Julie Brahmer
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being to determine the dose of the investigational drug MEDI4736 that is safe and tolerable in people with advanced solid tumors. MEDI4736 is an antibody that is made in the laboratory. An antibody is a natural protein made by our immune system that binds to other proteins and molecules to fight infection and its ill effects. MEDI4736 binds to another protein in the body and may prevent cancer growth by helping certain blood cells of the immune system eliminate the tumor. This is the first time MEDI4736 will be given to people. Thus, the effects of the drug, good and bad, and the correct dose of the drug to give are unknown. This study will also evaluate: how much MEDI4736 is in the blood at various times, whether the immune system becomes activated following use of MEDI4736 or the body produces antibodies,(proteins produced by the immune system) against MEDI4736, and the effect MEDI4736 has on cancer.
Last Update
07/01/2016 05:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.